Dalcetrapib
As of the edition of 20 October 2026, Dalcetrapib is a small molecule: in active development; acts on CETP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 16, 1 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Dalcetrapib.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CETP | Cholesteryl ester transfer protein | P11597 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 9 | 0 | 0 |
| Phase 3 | 5 | 3 | 1 | 1 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Japan Tobacco | Lead sponsor of trials | 2000 to now |
| Akros Pharma | Lead sponsor of trials | 2002 to now |
| Roche | Lead sponsor of trials | 2005 to now |
| DalCor Pharmaceuticals | Lead sponsor of trials | 2023 to now |